Search
Digoxin Immune Fab (Ovine)
go.drugbank.com/drugs/DB00076ApprovedDigoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Doxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigational[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
CX501
go.drugbank.com/drugs/DB05174InvestigationalCx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of … It is developed by Cellerix and is in phase I of clinical trials.
Dexketoprofen
go.drugbank.com/drugs/DB09214ApprovedInvestigationalWithdrawnDexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties .
Mixtures: STADIUM-T, TİO-DEXİREN 25MG/ 4 MG FİLM KAPLI TABLET, 20 ADETNecitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnIt functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression … Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression
Rutin
go.drugbank.com/drugs/DB01698ApprovedInvestigationalIt has been used therapeutically to decrease capillary fragility.
Mixtures: Rose Hips 500plus Nu LifeSynonyms: 3-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-oneTeprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigationalapproved by the FDA in January 2020 for the treatment of TED. … [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the … The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer.
Copper histidinate
go.drugbank.com/drugs/DB32041Approved[A275383,T903] In patients with the disease, defects in this transporter lead to the entrapment of copper in the intestinal lining and a subsequent inability to absorb it into the bloodstream, resulting … [A275383] This deficiency prevents the proper function of copper-dependent enzymes, leading to failure to thrive, neurodegeneration, connective tissue abnormalities, and the hallmark symptom of "kinky"
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.